000 01372 a2200361 4500
005 20250515090946.0
264 0 _c20071206
008 200712s 0 0 eng d
022 _a1083-7159
024 7 _a10.1634/theoncologist.12-9-1070
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSuperfin, Diana
245 0 0 _aCommentary: Oncologic drugs in patients with organ dysfunction: a summary.
_h[electronic resource]
260 _bThe oncologist
_cSep 2007
300 _a1070-83 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAntibiotics, Antineoplastic
_xadministration & dosage
650 0 4 _aAntimetabolites, Antineoplastic
_xadministration & dosage
650 0 4 _aAntineoplastic Agents
_xadministration & dosage
650 0 4 _aAntineoplastic Agents, Phytogenic
_xadministration & dosage
650 0 4 _aCase-Control Studies
650 0 4 _aHumans
650 0 4 _aKidney
_xdrug effects
650 0 4 _aKidney Diseases
_xphysiopathology
650 0 4 _aLiver
_xdrug effects
650 0 4 _aLiver Diseases
_xphysiopathology
650 0 4 _aProspective Studies
650 0 4 _aTopoisomerase Inhibitors
700 1 _aIannucci, Andrea A
700 1 _aDavies, Angela M
773 0 _tThe oncologist
_gvol. 12
_gno. 9
_gp. 1070-83
856 4 0 _uhttps://doi.org/10.1634/theoncologist.12-9-1070
_zAvailable from publisher's website
999 _c17435640
_d17435640